Henlius Receives the NMPA IND Clearance for HLX319 (Biosimilar, Phesgo)

Why It Matters

The clearance paves the way for a lower‑cost, convenient HER2 therapy in China, potentially expanding patient access and intensifying competition in the biologics market.

Key Takeaways

• IND cleared for HLX319, biosimilar Phesgo, in China
• Targets HER2+ early, locally advanced, and metastatic breast cancer
• Uses Henlius' HLX11 and Hanquyou antibodies with Henozye hyaluronidase
• Subcutaneous injection completes in 5‑8 minutes, no weight dosing
• Could lower costs and expand access to HER2 therapy

Pulse Analysis

HER2-positive breast cancer remains one of the most aggressive subtypes, accounting for roughly 20% of all cases worldwide. The combination of pertuzumab and trastuzumab has become a standard of care, delivering synergistic blockade of the HER2 receptor. Roche’s Phesgo, a fixed‑dose subcutaneous (SC) formulation that also contains hyaluronidase, shortens infusion time to five‑to‑eight minutes and eliminates weight‑based dosing, while matching the efficacy and safety of traditional intravenous regimens. This convenience has driven strong demand for SC options in both mature and emerging markets.

Henlius, a fast‑growing Chinese biopharma, secured IND clearance from the National Medical Products Administration for HLX319, its biosimilar to Phesgo. The investigational product pairs Henlius’ own pertuzumab candidate, HLX11, with its trastuzumab analogue, Hanquyou, and incorporates the hyaluronidase excipient Henozye to enable SC delivery. HLX11 is simultaneously under review by regulators in Canada and the European Union, signaling Henlius’ ambition to launch a globally competitive HER2 portfolio. The IND approval clears the path for Phase III trials in neoadjuvant, adjuvant, and metastatic settings within China.

The clearance could reshape China’s HER2 treatment landscape by introducing a lower‑cost, SC biosimilar that eases hospital workflow and improves patient quality of life. Subcutaneous administration reduces chair time and eliminates the need for weight‑based calculations, translating into measurable savings for both providers and payers. Moreover, a domestically produced biosimilar may benefit from favorable pricing policies, expanding access for patients who previously faced prohibitive costs. As more Chinese innovators achieve IND status for complex biologics, the market is poised for intensified competition and accelerated adoption of patient‑centric delivery formats.